anatumomab mafenatox   Click here for help

GtoPdb Ligand ID: 9947

Synonyms: 5T4FabV13SEAD227A | ABR 214936 | ABR-214936 | ABR214936 | pMB125 | PNU 214936 | PNU-214936 | PNU214936 | TTS-CD2
Immunopharmacology Ligand
Compound class: Antibody
Comment: Anatumomab mafenatox (ABR-214936) is a fusion protein containing an engineered 5T4 Fab moiety fused via the C terminus of the heavy chain to a mutated form of the Staphylococcal enterotoxin A (SEA) superantigen [1]. SEA is secreted by the pathogen and it stimulates a massive MHC class II-T cell receptor-mediated polyclonal T cell activation, which results in the release of large amounts of cytotoxic and proinflammatory cytokines. Anatumomab mafenatox targets the destructive power of SEA to 5T4-expressing tumour cells. The Asp227Ala mutation is the SEA moiety is designed to reduce MHC class II binding affinity so as to reduce killing of MHC class II positive cells.
Click here for help
Immunopharmacology Comments
Anatumomab mafenatox is a novel anti-tumour immunotherapy that targets cancer cells that express trophoblast glycoprotein 5T4, but spares normal adult tissues which do not express 5T4 [1].
Immunopharmacology Disease
Disease X-Refs Comment References
Renal cell carcinoma Disease Ontology: DOID:4450
Phase 2 clinical immuno-oncology candidate for advanced RCC. 2